Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Statement on Nuplazid Drug

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

The Parkinson’s Foundation is closely monitoring the recent reports on Nuplazid. At this time, we are recommending that patients on this drug consult with their neurologists about the risks and benefits of the treatment. The FDA will continue to monitor the drug’s use and safety, but they have not identified a specific safety issue that isn’t already described in the drug’s label. 

Parkinson’s disease psychosis is typically seen in advanced stages of Parkinson’s disease involving elderly patients. Treating Parkinson’s disease psychosis is a multi-step process that begins with talking to your health care team. They will follow a series of steps to figure out how best to address symptoms. For more information on this topic, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636). 

Please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call ACADIA Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).

For more information about Psychosis and Parkinson’s Disease:

Listen to our podcast

Read our recent blog article

Read more in our free book, "Psychosis: A Mind Guide to Parkinson's Disease"

Watch our Expert Briefings: Parkinson's Disease Psychosis: Hallucinations, Delusions and Paranoia

Tuesday, April 10, 2018
Parkinson’s Foundation Welcomes Paul H. Nathan to Board of Directors
Wednesday, May 3, 2017

New York, NY and Miami, FL — The Parkinson’s Foundation is pleased to announce the election of financial services executive Paul H. Nathan of San Francisco, CA, to its Board of Directors. The appointment was announced following a meeting of the board on April 27.

Parkinson’s Foundation to Host “World Without Parkinson’s” Scientific Symposium on June 1 in NYC
Friday, April 21, 2017

The Parkinson’s Foundation invites health innovators to join World Without Parkinson’s on Thursday, June 1 in New York, NY. The cutting-edge scientific event marks the 200th anniversary of James Parkinson’s, “An Essay on the Shaking Palsy.”

FDA Allows Marketing of a Genetic Test for Medical Conditions Including Parkinson’s
Thursday, April 6, 2017

Earlier today, the US Food and Drug Administration (FDA) announced that it will allow direct marketing to consumers of a genetic test that identifies predispositions for 10 medical conditions, including Parkinson’s. Such tests are referred to as direct-to-consumer or DTC.

Parkinson’s Foundation to Host 60th Anniversary Gala on Wednesday, May 31
Monday, March 20, 2017

The 60th Anniversary Gala to benefit Parkinson’s Foundation will take place Wednesday, May 31, 2017 in the Garden Terrace Room at the New York Botanical Garden in the Bronx, NY.  The Gala marks the 60th Anniversary of both the Parkinson ’s Disease Foundation (PDF) and the National Parkinson Foundation (NPF), the legacy organizations of the Parkinson’s Foundation and recognizes their

Parkinson’s Foundation Mourns the Passing of Lewis P. Rowland, M.D.
Friday, March 17, 2017

The Parkinson’s Foundation mourns the loss of Lewis P. “Bud” Rowland, M.D., Emeritus member of its Board of Directors and longtime champion of its work to end Parkinson’s. Dr. Rowland, who also served as President of the Parkinson’s Disease Foundation (PDF) division of the Parkinson’s Foundation for many years, passed away on March 16.

Local Residents Raise Nearly $40,000 for Parkinson’s Research at Scotch & Sangria Event in Closter, NJ
Thursday, March 9, 2017

Proceeds From Fourth Annual Helping Hours Event Benefit Parkinson’s Foundation

Advocates Guide $16 Million in US Department of Defense Parkinson’s Research Funding for Second Straight Year
Tuesday, March 7, 2017

Recently, four Parkinson’s Foundation Research Advocates helped guide $16 million in government funding for Parkinson’s disease (PD) research. This is the second straight year in which our Research Advocates have served as consumer reviewers for research funded by the US Department of Defense (DoD). The group included:

Parkinson’s Foundation Receives Award to Develop National Recommendations to Improve Care for Women with Parkinson’s
Tuesday, February 28, 2017

NEW YORK CITY & MIAMI — The Parkinson's Foundationhas received a $250,000 award to develop new patient-centered recommendations to improve the health of women living with Parkinson’s disease.

Parkinson’s Foundation Invests $500,000 in Community-Driven Clinical Research To Ease Cognition, Sleep and Fatigue in Parkinson’s
Monday, February 27, 2017

Five New Awards Address Unmet Needs

New York, NY and Miami, FL — The Parkinson’s Foundation has awarded $500,000 for translational research grants to address critical unmet needs in Parkinson’s disease.  The investments jumpstart practical solutions to ease difficulties related to cognition, fatigue and sleep, all of which are debilitating yet under-recognized symptoms in Parkinson’s.

The Parkinson's Foundation’s Moving Day® Walks Fund Local Parkinson’s Programs in 2017
Monday, February 13, 2017

$13.7 million dollars raised over five years
 

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.